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In vitro inhibition of human malignant brain tumour cell
line proliferation by anti-urokinase-type plasminogen
activator monoclonal antibodies
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Summary A brain tumour-associated marker, urokinase (UK), was investigated using rabbit anti-UK polyclonal and munne anti-UK
monoclonal antibodies, which were prepared by immunization with low molecular weight UK (LMW-UK) and high molecular weight urokinase
(HMW-UK) synthetic peptide respectively. The polyclonal antibody cross-reacted with both LMW-UK and HMW-UK. whereas the murne
MAbs were specific for HMW-UK. These immunological probes were used to study urokinase in glioma extracts, tissues, sera and cell lines
that had been prepared from prmary cultures of freshly dissected gliomas. Radioimmunoassays showed that glioma extracts had much
higher level (5- to 44-fold) of UK than normal human brain extracts. This result was confirmed by immunoblotting of electrophoresis gels of
glioma and human brain extracts. Immunohistochemical study using anti-UK MAb demonstrated much higher levels of UK in glioma tissue
than normal brain tissue. Immunohistochemical study using anti-UK MAbs localized UK on the cell surface of glioma cells. Anti-UK MAbs
inhibited the proliferation of AA cell lines and GB cell lines (500c to > 90%) and exerted minor effects (< 20%) on normal human liver, intestine
and lymphocyte cell lines. Taken together, these results suggest that anti-UK MAbs may have therapeutic potential for human gliomas and
cancer metastasis.
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Considerable indirect exidence from model tumour svstems has
accumulated to show that invasion and metastasis in solid tumours
require the action of tumour-associated proteases that promote the
dissolution of the surrounding tumour matrix and the basement
membranes. Receptor-bound urokinase-txpe plasminogen acti-
xvator (uPA) appears to play a key role in these exents (Dano et al.
1986: Duffx. 1987 and Zucker. 1988).
Plasminogen actix ator is a serine protease existing in two forms
known as tissue type (tPA) and urokinase tx-pe (uPA) (Sobel et al.
1952: Giinzler et al. 1982a.b: Nielsen et al. 1982: Wun et al. 1982:
Salerno et al. 1984: Verde et al. 1984: Riccio et al. 1985). uPA
converts plasminogen into plasmin and thus mediates pericellular
proteolysis during cell migration and tissue remodelling, under
phy siological and pathophy siological conditions (Gnrmann et al.
1976: Gerdin and Saldeen. 1978: Reich. 1978: Plow et al. 1982:
Salo et al. 1982: W'ainber! et al. 1982: Booth et al. 1983 and NC,
and Kellen. 1983). uPA is secreted as an enz\-maticall\ inactive
proenzyme by tumour cells and stroma cells. uPA exerts its proteo-
Itic function on normal cells and tumour cells as an ecoenzyme
after haxving bound to a hi-h-affinitv cell-surface receptor. After
bindincg. pro-uPA is activated bv senine proteases and the cysteine
proteases. Receptor-bound enzymaticallx active uPA converts
plasminogen to plasmin. Ahich is bound to a different low-afflnitv
receptor on tumour cells. Plasmin then degrades components of
the tumour stroma and may actixate procollagenase txype IV. which
degrades collagen type IV. a major part of the basement
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membrane. Hence. receptor-bound uPA v ill promote plasminogen
actixation and thus the dissolution of the tumour matrix and the
basement membrane. which is a prerequisite for invasion and
metastasis.
Plasminogen actix ators in tumours of the central nernous
sx stem haxe not been studied extensix ely despite the intense
in estigation into their possible role in cancer biologv Hoosein et
al. 1991: Foekens et al. 1992: Hollas et al. 1992: Kobaxashi et al.
1992. 1993; Reith and Rucklidge et al. 1992: Sumivoshi et al.
1992: Hsui et al. 1993: Janicke et al. 1993: Pujade-Lauraine et al.
1993: Yamashita et al. 1993: Achbarou et al. 1994: Bianchi et al.
1994: Bouchet et al. 1994: Moser et al. 1994 and Young et al.
1994). In this study. we report the oxverexpression of urokinase-
type plasminogen activator in -liomas. its localization on human
glioma cell surface and the antitumorigenic effect of anti-UK
MAbs against human malignant brain tumour cell lines.
MATERIALS AND METHODS
Materials
Brain tumour extracts were prepared from wet tissue samples (2 g)
homocenizedby biohomogenizer (Fisher Scientific) in 10 mxis phos-
phate-buffered saline (PBS) buffer (pH 7.2) at 4 C wxith 100 nvm
phenylmethylsulphonxl fluoride (PPMSF) as protease inhibitor. After
centrifugation ( 17 000 r.p.m. 90 min at 4-C) ofthe samples. protein
concentrations in the supematants w-ere determined.
Frozen sections (about 5 zm in thickness)w(ere prepared and
fixed in 95%7c ethanol and stored at -70 C or processed directly.
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Figure 1 Binding of anti-UK antibodies to malignant glioma and normal
brain tissue extracts. (A) Urokinase content of malignant giora (A, 0) and
normnal human brain (I, _) extracts were determined using anti-UK MAb4
(A, ^I) and rabbit anti-UK antibody (0, ). Binding of (B) anti-UK MAb4 and
(C) rabbit anti-LMW-UK to extracts of four additional gliobastomas (GBM
1-4), four astrocytomas (AA 5-8) and three GBM cell culture supematants
(CL1-CL3). UK is a positive control of HMW-UK Note that UK levels
increased 5-to 44-fold in GBM and AA tissue
Cell lines (Cl -Cl,) were prepared from freshly removed tumours
of glioma patients. Anti-UK MAbs were prepared by immuniza-
tion with high molecular weight urokinase synthetic peptides.
They showed exquisite specificity to UK and their binding was
blocked by using an excess of the immunogen (this will be
described in a separate publication), whereas rabbit anti-UK poly-
clonal antibody was prepared by immunization with LMW-UK.
METHODS
Binding studies
Tumour extracts offive glioblastoma patients and five astrocytoma
patients were freshly prepared. Their protein concentration as well
as that of sera from nine brain tumour patients and nine normal
individuals, was detennined- Equal concentrations of extracts and
sera (2.5 jg 50 jl-l per well of50 jg ml-' extract) as well as tissue
culture supernatants of glioma cell lines were tested for urokinase.
This was performed by using rabbit anti-LMW-UK polyclonal anti-
body and anti-HMW-UK MAbs and employing radioimmunoassay
(RIA) as described (Abaza and Atassi. 1992). Briefly. tumour
extracts. sera and tissue culture supematants of glioma cell line.
used straight. were plated in triplicate on polyvinyl chloride plates
(3 h. 37°C). The plates were washed (6x) with PBS (pH 7.20) and
then blocked with 1% bovine serum albumin (BSA) (100 jl per
well. 1 h at 37°C). Anti-UK MAb or polyclonal antibodies. at
appropriate dilution. were then added and incubated overnight at
room temperature. The plates were then developed by using rabbit
antimouse Ig (1:1000 dilution. for h at 37°C) followed by ['1Th-
protein-A (200 000 c.p.m. per well. 2 h. room temperature) in the
case of anti-UK MAb and by using [''21]-goat anti-rabbit IgG
(200 000 c.p.m. per well. 2 h. room temperature) in the case of
rabbit anti-LMW-UK antibodies. The plates were washed. dried.
cut out and counted on a gamma counter. Non-specific binding was
monitored using unrelated antigen (BSA or casein).
Gel elecrphoesis
The experiment was performed as described (Laemmli. 1970) in
10% acrylamide sodium dodecyl sulphate gels. All samples were
reduced using beta-mercaptoethanol. Brain tumour and normal
brain samples were loaded on the gel at 30 jg ofprotein per lane.
Western immunoblotting
SDS gels were transferred to nitro-cellulose as described (Towbin
et al. 1979 and Bumette 1981). The membrane was blocked by 3%
BSA and 0% normal goat serum for 1 h at room temperature.
then washed with TBST buffer (50 nmi Tris pH 8. 150 insm sodium
chlonrde and 0.05% Tween-20) and incubated with anti-UK MAb
for 3 h at room temperature. The membrane was washed as
mentioned above and then treated with goat anti-mouse Ig alkaline
phosphatase conjugate ( 1:1000 dilution. 2 h at room temperature).
The freshly prepared substrate (NBT. BCIP in alkaline phos-
phatase buffer 100 Tris pH 9.5. 100 mst sodium chloride and
5 mtm magnesium chloride) was added and incubated for up to 30
min. after which the reaction was stopped and the membrane
washed and dried.
Immunofluorescence of glioma and normal brain
tissues
Sections (5 jm thick) of glioma and human brain were strained
with anti-UK MAb for 1 h in a humid chamber at 37C. The slides
were washed (3x 5 min each) with PBS-Mg/Ca. then treated with
fluoresceinated goat anti-mouse Ig conjugate (1:30 dilution) for
1 h at 37°C in a humidified chamber. The slides were washed with
PBS-Mg/Ca. mounted with buffered glycerol and viewed with an
immunofluorescence microscope.
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Fgure 2 Immunofluorescence study on human gioma frozen secions and cels. Secions of human maligaMgloma (A) and nonmal brain (B) tissues were
stained with anti-UK MAb folbwed by fluoresceinated goatantni-ouse Ig conjugate. Whereas gloma gave very striing immunofluorescence staining, norral
brain exhibited much less staining for uPA. Cells from bg-phase culture ofglioma were applied to poly-L-Iysine-coated slides and air dried at room temperature.
Cells were fixed as described under Materials and methods and stained with either anti-UK MAb (C) or normal mouse Ig (D) of the same isotype and
concenration as negative control, folbwed by fluoresceinated goat anb-mouse Ig conjugate. It is dear that UK is loalized on the cell surface of glioma cells (C)
Cell-surface localization of urokinase on human glioma
cells
A single cell suspension was prepared from log-phase culture of
glioma cells. Cells were apphed topol)-L-lysine-coated slides and
air dried at room temperature. Cells were fixed and slides were
blocked with 31% BSA-PBS for 1 h at room temperature. washed
(3x) with PBS (pH 7.2). Anti-lUK MAb or normal mouse Ige ofthe
same class and immunoglobulin concentration (as a negative
control) was than added and incubated for 1 h at 37°C in a humid-
ified chamber. Slides were washed (3x) with PBS and stained with
fluoresceinated goat anti-mouse Ige conjugate (at 1:30 dilution) for
I h at 37 C in a humidified chamber. Cells were then washed (3x)
with PBS. mounted in buffered glycerol and viewed through an
immunofluorescence microscope.
PH]Thymidine uptake by glioma cell lines
[ H]Thymidine uptake was used to monitor the proliferation of
three glioma cell lines (one anaplastic astrocvtoma. AA. two
glioblastoma multiforme. GB1 and GB2). In this experiment
various cell numbers (in triplicate) ofeach cell line were incubated
with a fixed amount of [ Hlthymidine (2 jCi per well) for 18 h at
37°C in a humidified 5% carbon dioxide atmosphere. The cells
were then harvested, washed (lOx) with distilled water and the
amount of radioactivity on the filter was measured using a beta
counter.
Effect of radiation (10 Gy mim1) on glioma cell line
prolifertion
For our study. the negative control for glioma cell lines was
prepared by irradiation using caesium-137 gamma radiaton from a
Gammacell 1000. In this experiment. a fixed number of glioma
cell lines (50 1l per well of5 x I0W cells ml-'). which gave a strong
reliable [ H]thymidine incorporation signal. were irradiated for
various lengths of time (0-45 min). The ability of the irradiated
cells to incorporate [ H]thymidine was tested as mentioned in the
previous section.
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In vitro efficacy of anti-UK MAbs against human glioma
cell lines
The antiproliferative activities of four anti-UK MAbs towards
three glioma cell lines (one anaplastic astrocytoma. AA. and two
glioblastoma multi-forme. GB1 and GB2) were determined as
follows: a fixed number (50 gI per well of 5 x I05 cells per ml) of
glioma cell lines or normal human lymphocyte. intestine and liver
cell lines were seeded (in triplicate) on to a 96-well plate. Various
concentrations of each of anti-UK MAbs. normal mouse IgG and
IgM (Sigma), as a negative control, were then added to the cells.
The plates were incubated for 18 h at 37°C in a humidified. 5%
carbon dioxide atmosphere. Fixed amounts of [3H]-thymidine
(2 jCi per well) were added and the cells further incubated for
18 h. Cells were then harvested, washed (lOx) with distilled water
and the amount of radioactivity on the filter was measured on a
beta-counter.
Testing the cytolytic activity of anti-UK MAbs to human
glioma cell lines
Cytotoxicity of anti-UK MAbs [MAb UK4 and MAb AB3 (IgM)
MAb D4A8 and MAb UKS (IgG)] to glioma cells (2GB. IAA) was
tested using [3H]thymidine release assay. A fixed number of glioma
cels (50 Rl per well of 5 x 105 cells ml-') was inoculated into a 96-
well plate. CeUs were pulsed with [ H]thymidine (2 iCi per well)
and incubated for 18 h at 37°C in a humidified 5% carbon dioxide
atmosphere. Cells were washed (5x) with medium. Various concen-
trations (100 per well, in triplicate) ofeach anti-UK MAb. rmal
mouse IgG and IgM (as negative controls) were added and the ceUs
were incubated for 18 h at 37°C in a humidified 5% carbon dioxide
atnosphere. Cell supematants were removed and spun and a certain
volume of supernatants (70 jl) was monitored in a beta counter after
mixing with scintillation cocktail (Scinti Verse II. Fisher Scientific).
Testing glioma cell survival after anti-UK MAbs
treatbent
Glioma cells. normal human lymphocyte. liver and intestine cell
lines (50 jl of 5 x l05 cells ml-1) were incubated with anti-UK
MAbs (100 pl. in triplicate), unrelated monoclonal antibody ofthe
same isotype and concentration (to monitor non-specific lysis) and
tissue culture medium (to monitor spontaneous lysis) for 36 h in
5% carbon dioxide humidified atmosphere. Cells were then
stained with trypan blue and viewed microscopically.
RESULTS
Binding of anti-UK antibodies to malignant glioma and
normal brain exbtacts
Equal concentrations ofmalignant glioma and normal brain extracts
were analysed for their content of urokinase using anti-UK MAb4
and rabbit anti-LMW-UK. Glioma extracts contained a much higher
(5- to 44-fold) amount of UK than normal human brain extracts
(Figure IA). This result is confuimed by analysing extracts of four
other malignant glioblastomas (Figures IB and C: 1-4). four malig-
nant anaplastic astrocytomas (Figure IB and C: 5-8) and three
glioma cell line supernatants (Figure IB and C: Cl -C) using anti-
UK MAb4 (Figure IB) and rabbit anti-LMW-UK antibody. These
results were also confimed by immunofluorescence and immuno-
blotting studies.
A B C
FKgure 3 Immunoblottng of malignant glioma and human brain tssue
extracts. Equal concentratons of human maJignant glioma (Lane B) and
normal brain (Lane C) extracts were subjected to SDS-PAGE followed by
immunobottng on nitrocellose membrane, which is ten processed as
described under Materials and methods. HMW UK was used, on te same
gel, as positive control (Lane A)
Immunofluorescence study on human glioma frozen
sections and cells
The aim of the immunofluorescence experiments was to examine
the levels of UK in nine frozen sections of human malignant
glioma and normal brain tissues to confirm the results of RIA and
immunoblotting. Frozen sections of human malignant glioma
(Figure 2A) and normal human brain (Figure 2B) were immuno-
fluorescent stained for UK using anti-UK MAb4. The rlioma
tissue exhibited very striking immunofluorescence staining
compared with human brain. which gave much less staining for
UK. These data confirmed the results of RIAs (Figure 1.) To use
anti-UK MAbs for glioma therapy. a prerequisite ofrecognition of
glioma cell surface should be met. The ability of anti-UK MAb to
bind to glioma cell surface was investigated by indirect immuno-
fluorescence. Figure 2C gave very clear evidence for the localiza-
tion of uPA on the surfaces of glioma cells that showed no
fluorescence when treated with unrelated antibody (Figure 2D) as
a negative control for anti-UK MAb. Staining of nuclei or any
other cell organelles was excluded because the cell membrane is
impermeable to antibody. and when glioma cells were prepared for
surface staining they were fixed with paraformaldehyde but did
not permeabilize. so anti-UK mAbs would not be able to translo-
cate the cell membrane.
Immunoblotting of malignant glioma and human brain
extracts
Malignant glioma and human brain contents of UK were further
investigated by electrophoretic separation of their extracts
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Figure 4 In vitro efficacy of anti-UK MAbs against human gliona cell lines. The an-proliferative actvity of four anti-UK MAbs [two lgM MAbs: A B12B4 and B
AB3 and two IgG MAbs: C UK5 and D D4A8] towards three human glioma cell lines [one anaplastic astrocytoma, AA- (*) and two gliobblastoma murtforme, GB1
(-) and GB2 (A)], normal human liver ( ), intestine (A) and lymphblast (O) cell lines was studied as described in Materials and methods. One hundred per
cent [3H-thymidine incorporation was 34 418 c.p.m. (AA), 5902 c.p.m. (GB1); 163 757 c.p.m. (GB2); 71 143 c.p.m. (GB1); 163 757 c.p.m. (GB2); 71 143 c.p.m.
(liver cell line); 175 422 c.p.m. (intestine cell line) and 5126 c.p.m. (lymphocyte cell line). Irradiated AA, GB1, GB2, liver, intestine and lymphocyte cell lines gave
[3HJthymidine uptake signals: 2595 c.p.m.; 536 c.p.m.; 3775 c.p.m.; 6592 c.p.m.; 6822 c.p.m. and 351 c.p.m. respectively. (V) An average inhibitory effect of
normal mouse IgG or IgM on gliomas and normal human lines
Table 1 Inhibition of the proliferation of human malignant gioma cell lines by anti-urokinase type plasminogen activator
monockoa antibodies
% Inhibition
Human cell MAb-UK4 MAB-AB3 MAbS MAb-D4A8
lines (8 x 10-10H) (0.495 x 10-10 m) (1.63 x 1104 ) (0.665 x 104 m)
AA 97 60 84.33 52
GB1 88.9 77 70.17 70
GB2 99.35 68 88.75 60
Liver 20 18 - 19
Intestine 16.6 17 8.5 5
Lymphocyte 18 17.35 18 18
followed by immunoblotting using anti-UK MAb. Immuno-
blotting results showed verv high expression of UK in glioma
(Figure 3. lane B) compared with normal human brain (Figure 3.
lane C). again confirming the results obtained from RIA (Figure 1)
and immunofluorescence (Figure 2). studies. HMW-UK was used
as a positive control (Figure 3. lane A).
PHIThymidine incorporation by glioma cell lines
[1H]Thymidine uptake was employed to monitor the proliferation
of glioma cells. Various glioma cell numbers were tested for their
ability to incorporate a fixed amount of [iH]thymidine. The cell
number (5 x lIW cells ml-') that gave a strong reliable signal was
chosen for the subsequent studies (data not shown).
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UK4 and MAb AB3 (1gM): MAb D4A8 and MAb UKS (IgG)] and
three ghloma cell lines (2GB and IAA). Each l -sis experiment w-as
carried out in triplicate. Consistent results xWere obtained with
various glioma cell lines and anti-UK MIAbs exhibited efficacies
that x-aried from one MAb to another (Figure i). AB3 MAb is the
most efficient. exerting cytolv-tic activity at a much lower antibodv
concentration than the other anti-UK MAbs.
Testing glioma cells survival after anti-UK MAb
treatment
c-~- ; _ * STo test w-hether anti-UK MAbs w-ere able to INse the glioma cells
and not just arrest their proliferation. glioma cells w-ere incubated
2 -11 -10 -9 - -7 with anti-UK MAb (AB3 MAb) for 36 h at 37-C as described
Log MAb concentration (M) earlier. Cell sunrix-al was examined microscopicalI- after staininc
wxith trypan blue. Irrelexant monoclonal antibody of the same
Testing the cytoWtic actvity of anti-UK MAbs to glioma cells. isots pe and concentration and tissue culture medium was used to
idine release assay was employed to test the cytoyc acvty of
lAbs: (-)AB3. ( ~) UK4. (v) D4A8 and (I) UK5. Nommal mouse monitor the non-specific lvsis and spontaneous Ilysis respectivelv.
vas used as negative control for anti-UK MAbs, UK4 and AB3. Normal human lymphocyte. lihver and intestine were treated as
*ouse IgG (=-) was used as negative control for D4A8 and UK5 olloma and theirsurxix al was testedby dy e exclusion. Most ofthe
glioma cells retained trypan blue. whereas normal human lympho-
cyte. lixer and intestine cells excluded the dye (data not shownn.
Effect of radiation on glioma cell line proliferation
The negatixe control was cenerated by exposing the different
glioma cells to radiation for various durations (from 0 to 45 mini.
The time that completely destroved the ability of these cells to
proliferate was determined and used in the subsequent studies.
Glioma cells lost their proliferative actixvit after about 20 min
radiation. i.e. 200 Gx. Howexer. it was decided to use a longer
radiation time (45 mm = 450 Gy). (data not shown).
In vitro efficacy of anti-UK MAbs against human glioma
cell lines
The antiproliferative activities of anti-UK MAbs to human malig-
nant glioma cell lines. summarized in Figure 4 and Table 1.
show-ed that MAb UK4 inhibited the proliferation of the AA cell
line (97%). the GBl cell line (88.9%7). the GB2 cell line (99.35%7).
liver cell line (20%7c). intestine cell line (16.6%) and lymphocyte
cell line (18%7c) at a concentration 8 x l0-1"MN (Figure 4A).
MAbAB3 inhibited the proliferation of the AA cell (60%7). the
GBI cell line (77%). the GB2 cell line (68%7). the lixer cell line
(18%). the intestine cell line (17%c) and lymphocyte ceHl line
(17.35%7c) at a concentration 0.495 x 10-1) m (Figure 4B). MAb5
inhibited the proliferation of the AA cell line (84.33%). the GBI
cell line (70.19'i . the GB2 cell line (88.75%7r). the lixer cell line
(no inhibition). the intestine cell line (8.5%) and lymphocyte cell
line (18%7) at a concentration 1.63 x 10-1m (Figure 4C). MAb
D4A8 inhibited the proliferation of the AA cell line (52%7c). the
GB1 cell line (70%7c). the GB2 cell line (60%). the lixer cell line
(19%7). the intestine cell line (5%7) and the lymphocyte cell line
(18%7) at a concentration 0.665 x 10 NI (Figure 4D). Normal
mouse IgM or IgG had an average inhibitory effect of < 10%7c on
gliomas and normal human lines (Figure 4).
Testing the cytolytic activity of anti-UK MAbs to glioma
cells
The abilitv of anti-UK MAbs to ly-se the glioma cells was tested
using, [-H]thymidine release assay. four anti-UK MAbs [MAb
DISCUSSION
Plasminogen actixators in tumours of the central nerxous sxstem
have not been studied extensixely despite the intense investigation
of their possible role in cancer biology in general (Hoosein et al.
1991: Sumixroshi et al. 1992: Foekens et al. 1992: Hollas et al. 1992:
Kobayashi et al. 1992: Rucklidge. 1992: Hsui et al. 1993: Janicke et
al. 1993: Kobavashi et al. 1993: Pujade et al. 1993: Yamashita et al.
1993: Achbarou et al. 1994: Bianchi et al. 1994: Bouchet et al. 1994:
Moser et al. 1994: Young et al. 1994). The plasmin generating
sy stem is composed of plasminogen. which is a zymocen. and the
enzyme plasminogyen actixator (PA). w%-hich actix-ates plasminogen
to aenerate the potent protease plasmin. The high circulatine; lexels
ofplasminogen represent a reserx oir ofpotential proteolv tic activity.
which can be recruited by cells for functions requiring localized
extracellular proteoly sis. The actix ation ofplasminogen is regulated
by the amount of PA axailable: this step is controlled by the cells
that secrete the PA. The secretion of PA by cells seems to fluctuate
with their physiological or dexelopmental status (Reich. 1978:
Strickland. 1980). In the present studx glioma tissue showed a xern
large increase (5 to 44-fold) in UK lex els in alioma tissues
compared wxith normal human brain tissues (Figures 1-3). Enhanced
production ofplasminogen actix ator has also generally been associ-
ated w-ith some cellular responses to tumour promoters (Wigler and
Weinstein. 1976). retinoids (Wilson and Reich. 1978) and DNA
damagge (Miskin and Reich. 1980). Hich levels of PA haxe been
showxn in a wide variety ofhuman tumours (Ossowaski et al. 1973:
Wilson and Dowdle. 1979: Wilson and Beck. 1980: Webber et al.
1981: Hoosein et al. 1991: Foekens et al. 1992: Hollas et al. 1992:
Kobavashi et al. 1992 Sumixoski et al 1992: Janicke et al. 1993:
Pujade-Lauraine et al. 1993: Yamashita et al. 1993: Achbarou et al.
1994: Bianchi et al. 1994: Bouchet et al. 1994: Moser et al. 1994:
Young et al. 1994). The increase in PA levels in these studies xaried
from 3 to 60-fold. consistent xxith 5- to -4-fold in our study. xhen
compared ith normal tissue.
Plasminogen activators may be inxolxed in groxxth responses
(Kalderon. 1984). They may also represent an essential step in
promoting inxasixveness and metastasis. These processes require
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that certain cell types transgress the normal anatomical boundaries
of tissues and miarate in and out of different body compartments.
To allow such cellular migration. mechanisms that provide for the
focal degradation must be available. Although the enzymatic basis
for such degradation is not completely understood. several lines of
evidence have sucaested that extracellular proteol sis catalvsed by
the secretion ofplasminogen activators may play an important part
in the derradative events necessary for migration ofcells in tissues
(Reich. 1978). The increased presence of PA may lead to a hirher
level of both plasmin and collagenase. Plasmin generated by
tumour PA not only can destroy the adjacent extacellular matrix. it
may also result in normal cell injury and necrosis (Raymond.
1983). Although urokinase-type plasminogen activator plays a
central role in cancer invasion and metastasis. uPA is not the only
proteolv-tic enzyme involved in these processes: there are others.
such as metalloproteinases. cathepsins. etc. Ahether there is a
common or different pattern of proteolvtic enzymes amonr
Various metastatic cancer cells and whether UK-necative cancer
cells exist and to what extent is currently under investiwation.
An enzyme required for cell migration and tissue destruction.
i.e. to control the dissolution ofthe basement membrane and ofthe
extracellular matrix. should be sitting in the presence ofUK on the
glioma cell surface. The overexpression of UK and its presence on
the outer surface of glioma cells makes UK. therefore. a good
marker for immunotherapy of human glioma and tumour metas-
tasis. In this studv. the anti-tumorigenic activities of anti-UK
MAbs towards human glioma cell lines were evaluated. The
results (Firure 4 and Table 1) showed that anti-UK MAbs were
able to control the proliferation of glioma cells in vitro. Antibody
class seemed to affect the efficacy of the monoclonal antibody.
IgM-UK MAbs were more efficient than IgG counterparts. This
may be due to the fact that IOM is a pentamer. whereas IgG is a
monomer. The cvtolvtic activities of anti-UK MAbs to glioma
cells were then investicyated. The results in Fiure 5 showed the
ability of anti-UK MAbs to lyse glioma cells. The use of these
MAbs in vivo for immunotherapy of human gliomas requires the
evaluation of their effects on normal cells. The effects of anti-UK
MAbs on the three normal cell lines: liver. intestine and lympho-
cyte were < 20%7 (Figure 4). At that stage. it is not clear how anti-
UK MAbs kill the 2lioma cells.
Urokinase bound to hicrh-affinitv membrane receptor is not
readily degraded or endocvtosed. Also. the interaction of UK with
glioma cells could be considered as that of hormone with its
membrane receptor. The re ion within the A-chain of M 55 °°°
UK. which is homologous to murine epidermal growth factor. has
been considered as a growth factor domain that exerts autocnrne
effects. One possible explanation for the observed antitumorigenic
effects of UK MAbs is that bindinc of anti-UK MAbs to UK-
bound receptor may stimulate endocytosis of UK-receptor
complex. This may abolish the autocrine effect of the UK-bound
receptor and cause rlioma cell injury- and necrosis. In summary.
our results demonstrated that anti-UK MAbs could be a v-ery -alu-
able reagent for cancer immunotherapy and generating anti-metas-
tasis drugs.
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ABBREVIATIONS
AA. anaplastic astrocytoma: GB. glioblastoma multiforme: GCS.
glioma cell line supernatant: H1MW-UK. high molecular weight
urokinase: LMW-UK. low molecular weight urokinase: PA. plas-
minogen activator: uPA. urokinase tvpe plasminogen activator.
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